Restore freedom for workers to negotiate their employment agreements from day one by removing the 30-day rule. This means ...

The shared structures that have underpinned global cooperation for years are crumbling, according to world leaders. Can the international rules-based order be saved, and how could the future look ...

When people in 25 countries were asked what makes them proud of their country, at least some cited their political system and economy.

Total Revenue Increased 16% and Core Revenue* Grew 16% over the prior year –– 2025 Net Income of $44.5 million versus $49.1 million in 2024 –– Adjusted EBITDA* in 2025 up 14% to $113.6 million –– ...

With the opening formalities finally complete, Parliament this week is solely focusing on legislation, including the first members' day for the year.

Whenever criticism against public officials is written and published, in the name of freedom of speech, many onion-skinned politicians react with suing for libel. Can libel prosper against the ...

In the nearly four years since Russia’s unprovoked full-scale invasion of Ukraine, the war has repeatedly confounded expectations. A conflict that many analysts anticipated would be short and ...

KOTA KINABALU, Malaysia — In recent times, crises have been erupting across the world with relentless frequency, and it has been a while since many have closely followed developments in Ukraine.

By Allen Chesser Carolina Journal As a state representative for North Carolina’s General Assembly (House District 25), I’ve spent years fighting for hardworking families in our communities. But one ...

A MAYO man has been fined €2,750 after carrying out unauthorised works involving the clearing of vegetation and the use of machinery within the Lough Corrib Special Area of Conservation (SAC).

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a clinical-stage biotechnology company that has positioned itself in the regenerative medicine space ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...